PR Newswire HONG KONG, BEIJING and BOSTON, June 6, 2025 HONG KONG, BEIJING and BOSTON, June 6, 2025 /PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology start-up company focusing on genome editing therapeutic ...
PR Newswire WUXI, China and SHANGHAI, May 16, 2025 WUXI, China and SHANGHAI, May 16, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates its ...
PR Newswire SAN DIEGO, May 15, 2025 SAN DIEGO, May 15, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data from the Phase 3 CAHtalyst™ Adult and Pediatric studies of CRENESSITY™ (crinecerfont). The data ...
PR Newswire PHILADELPHIA and NEW ORLEANS, May 15, 2025 Landmark Study from CHOP and Penn Medicine Showcases the Power of Customized Gene Editing Therapy to Treat Patient with Rare Metabolic Disease PHILADELPHIA and NEW ORLEANS, May 15, ...
PR Newswire LONDON, May 14, 2025 LONDON, May 14, 2025 /PRNewswire/ -- Kaerus Bioscience ("Kaerus" or "the Company"), a clinical stage biopharmaceutical company created by Medicxi for the development of therapeutics for rare genetic syndromes ...
PR Newswire HENDERSON, Nev., May 13, 2025 FDA has approved an aggressive stem cell clinical trial, offering potential new relief through intravenous (IV) administration. HENDERSON, Nev., May 13, 2025 /PRNewswire-PRWeb/ -- "We at L2 Bio ...
PR Newswire MIDDLETON, Mass., May 12, 2025 First Patient Dosing Anticipated in Second Half of 2025 Additional Details to be Provided by Webinar in Coming Months MIDDLETON, Mass., May 12, 2025 /PRNewswire/ -- MavriX Bio, a ...
PR Newswire ?COLUMBUS, Ohio, May 12, 2025 ?COLUMBUS, Ohio, May 12, 2025 /PRNewswire/ -- Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has ...
PR Newswire SHANGHAI, May 10, 2025 SHANGHAI, May 10, 2025 /PRNewswire/ -- Skyline Therapeutics, an innovation-driven clinical-stage gene therapy company focused on developing unique and novel solutions for rare and severe diseases, today ...
PR Newswire AUSTIN, Texas, May 6, 2025 License Expands Genprex's Portfolio of Oncology Gene Therapy Technologies AUSTIN, Texas, May 6, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene ...
New study finds genetic modifiers control human mutation rates, revealing how populations evolve and risk for genetic diseases may vary.
New gene discovery in Fanconi Anemia reveals a more severe form of the disorder and offers fresh insights that could lead to improved treatment options.
A molecular mechanism where impaired tRNA splicing disrupts cranial neural crest cells, revealing MYCN, DDX1, and tRNA processing defects as risk factors for orofacial clefts.
Genetic analysis reveals that dire wolves are not gray wolves’ ancestors but a separate species, reshaping evolutionary knowledge after 12,500 years.
A faulty FLCN gene may affect 1 in 3,000 people, raising their risk of pneumothorax, but shows a much lower kidney cancer risk.
Subscribe to our Free Newsletters!
Medindia's policies are aligned with the United Nations Sustainable Development Goals (SDGs) - SDG 3, SDG 4, SDG 5, SDG 6 , SDG 10 & SDG 12.
Disclaimer - All information and content on this site are provided for informational and educational purposes only. They should NOT be used for the diagnosis or treatment of any health-related condition or disease. Always consult a qualified healthcare professional for medical advice, diagnosis, or treatment. Full Disclaimer
Advertise with us | Medindia Copyright | Privacy Policy | Terms of Use © All Rights Reserved 1997 - 2025
Careers